NBC News, CNN: Company reports Alzheimer's drug study data
UC researcher says impact was small, recommends 'cautious optimism'
Japanese drugmaker Eisai recently reported cognitive decline was slowed by 27% after 18 months for patients with early-stage Alzheimer's who were given experimental drug lecanemab. The results have not yet been peer-reviewed.
The University of Cincinnati's Alberto Espay, MD, was not involved in the trial and provided his expert analysis to NBC News and CNN. He said the benefit to patients was "small" and fell below the threshold of what would be considered meaningful to a patient, but added that "patients can view this with cautious optimism."
Espay, professor of neurology in the UC College of Medicine, director and endowed chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders at the UC Gardner Neuroscience Institute and a UC Health physician, said that while the results appear to be positive, the single trial is unlikely to prove that amyloid plaques are responsible for the decline in mental function often seen in patients.
Espay argues that amyloid plaques are a “consequence, not a cause” of Alzheimer’s disease. Cognitive impairment, he said, could be due to a decline in levels of a specific brain protein called amyloid-beta peptide, which then leads to the accumulation of amyloid plaques in the brain.
Featured photo at top courtesy of Unsplash.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.